NR3C2 and type 2 diabetes mellitus: The FIDELIO-DKD and FIGARO-DKD trials, as well as FIDELITY, demonstrated a beneficial effect of MR antagonism by finerenone on renal and cardiovascular outcomes across patients with CKD and T2D [20,21,22].